Eli Lilly and Peptron entered a non-exclusive Platform Technology Feasibility and Evaluation Agreement in October 2024 that grants Lilly limited rights solely for internal R&D and technical assessment of the ultrasonic spray-dried PLGA microsphere SmartDepot sustained-release platform on peptide candidates. The deal explicitly separates this evaluation stage from any potential future commercial license or technology transfer and was extended to a maximum of 24 months ending October 7, 2026. Nearly two years later, no binding commercialization agreement has been announced, preclinical work on candidates including GLP-1 assets has expanded modestly into CNS indications, and Lilly has separately partnered with Camurus on competing long-acting delivery technology. With only weeks remaining and no recent catalysts or disclosed progress toward commercial terms, trader consensus heavily favors resolution to “No.”
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert13% Chance
$11,314 Vol.
$11,314 Vol.
6. Okt. 2026
13% Chance
$11,314 Vol.
$11,314 Vol.
6. Okt. 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron entered a non-exclusive Platform Technology Feasibility and Evaluation Agreement in October 2024 that grants Lilly limited rights solely for internal R&D and technical assessment of the ultrasonic spray-dried PLGA microsphere SmartDepot sustained-release platform on peptide candidates. The deal explicitly separates this evaluation stage from any potential future commercial license or technology transfer and was extended to a maximum of 24 months ending October 7, 2026. Nearly two years later, no binding commercialization agreement has been announced, preclinical work on candidates including GLP-1 assets has expanded modestly into CNS indications, and Lilly has separately partnered with Camurus on competing long-acting delivery technology. With only weeks remaining and no recent catalysts or disclosed progress toward commercial terms, trader consensus heavily favors resolution to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Markt eröffnet: May 5, 2026, 8:02 PM ET
Volumen
$11,314Enddatum
7. Okt. 2026Markt eröffnet
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron entered a non-exclusive Platform Technology Feasibility and Evaluation Agreement in October 2024 that grants Lilly limited rights solely for internal R&D and technical assessment of the ultrasonic spray-dried PLGA microsphere SmartDepot sustained-release platform on peptide candidates. The deal explicitly separates this evaluation stage from any potential future commercial license or technology transfer and was extended to a maximum of 24 months ending October 7, 2026. Nearly two years later, no binding commercialization agreement has been announced, preclinical work on candidates including GLP-1 assets has expanded modestly into CNS indications, and Lilly has separately partnered with Camurus on competing long-acting delivery technology. With only weeks remaining and no recent catalysts or disclosed progress toward commercial terms, trader consensus heavily favors resolution to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$11,314Enddatum
7. Okt. 2026Markt eröffnet
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly and Peptron entered a non-exclusive Platform Technology Feasibility and Evaluation Agreement in October 2024 that grants Lilly limited rights solely for internal R&D and technical assessment of the ultrasonic spray-dried PLGA microsphere SmartDepot sustained-release platform on peptide candidates. The deal explicitly separates this evaluation stage from any potential future commercial license or technology transfer and was extended to a maximum of 24 months ending October 7, 2026. Nearly two years later, no binding commercialization agreement has been announced, preclinical work on candidates including GLP-1 assets has expanded modestly into CNS indications, and Lilly has separately partnered with Camurus on competing long-acting delivery technology. With only weeks remaining and no recent catalysts or disclosed progress toward commercial terms, trader consensus heavily favors resolution to “No.”
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen